Presenting author
George Nomikos
4 presentations
EP01-1056. LB-102 in patients with bipolar I disorder experiencing a major depressive episode: Phase 2, double-blind, placebo-controlled trial design (ILLUMINATE-1)
PS01-1019. LB-102 effect on dopamine D2 autoreceptors: Results from a preclinical study evaluating dopamine efflux in rat nucleus accumbens using microdialysis
PS01-1156. Effects of LB-102 on cognitive performance in patients with schizophrenia: Post hoc analyses from the phase 2 randomised NOVA-1 trial
PS01-1226. Phase 3 clinical development program of LB-102 in schizophrenia: A double-blind placebo-controlled trial (NOVA-2) and an open-label extension study (NOVA-3)